Navigation Links
Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
Date:6/4/2008

DENVER, June 4 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, is exhibiting its AspirinWorks(R) Test at the American Diabetes Association's 68th Scientific Sessions. The exhibits are open Saturday through Monday, June 7 - 9, 2008, at the Moscone Convention Center in San Francisco, Calif.

This marks the first time the AspirinWorks test will be exhibited at the American Diabetes Association (ADA) Scientific Sessions. Corgenix representatives will be on-hand during the conference at booth 738 to answer questions about the AspirinWorks Test, including ongoing clinical research and the relationship among diabetes, aspirin effect and cardiovascular disease.

Corgenix is presenting an abstract on aspirin effect and diabetes during the general poster session on Saturday, June 7 in Hall D from 11:30 a.m. until 1:30 p.m. The abstract examines possible differences between healthy and diabetic men and women in heart attack and stroke risk reduction based on their response to the anti-clotting effects of aspirin.

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at http://www.aspirinworks.com.

It is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type of aspirin is appropriate for them to achieve the most benefit with the fewest side effects.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
2. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
3. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
4. Corgenix Signs Technology Licensing Agreement With Japanese Government
5. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
6. MagSense to Exhibit Its Scientific and Clinical Applications at International Magnetic Carriers Conference
7. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
8. Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images
9. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
10. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
11. Biotechnology Leader to Exhibit at Upcoming Trade Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):